miR-30e-5p as predictor of generalization in ocular myasthenia gravis

Liis Sabre¹, Paul Maddison², Sui H. Wong³, Girija Sadalage², Philip A. Ambrose², Gordon T. Plant³ & Anna R. Punga¹

¹Department of Neuroscience, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden
²Department of Neurology, Nottingham University Hospitals NHS Trust, Queens Medical Centre, Nottingham, Nottinghamshire, United Kingdom
³Department of Neuro-ophthalmology, Moorfields Eye Hospital NHS Foundation, Trust, London

Abstract

Objective: To determine a predictive factor for the risk of conversion from ocular myasthenia gravis (OMG) to generalized MG (GMG) in a prospective study. Methods: RNA was isolated from serum samples and detection of microRNA (miRNA) expression analyzed with qPCR. In the discovery set, 179 human miRNAs were assayed for profiling of five OMG patients and four age- and gender-matched healthy controls. Based on the specific accumulation pattern of 19 miRNAs from the discovery set, in addition to miRNAs previously found elevated in generalized MG (GMG; miR-150-5p and miR-30e-5p), 21 miRNAs were subsequently analyzed in a validation cohort of 83 OMG patients (82 immunosuppression treatment naive; 49 male) within 3 months of diagnosis and at a follow-up visit (median duration 28 months from first visit).

Results: Thirteen patients generalized 14.8 ± 12.0 months after the diagnosis and the majority (85%) belonged to the late onset MG group. Two miRNAs were significantly higher in secondary GMG (SGMG) patients compared to OMG patients with late onset MG: miR-30e-5p (9.1 ± 0.5 vs. 6.3 ± 0.9; P < 0.0001) and miR-150-5p (7.4 ± 1.1 vs. 6.4 ± 1.1; P = 0.01). The sensitivity for miR-30e-5p in differentiating OMG and SGMG was 96% in all OMG patients and 100% in late onset OMG patients. Interpretation: This is the first study to describe a potential predictive factor associated with the risk of generalization for patients with OMG. Raised levels (>8) of miR-30e-5p at initial presentation in patients with ocular MG symptoms, give a predictive cut-off for subsequent generalization of 96–100%.

Introduction

Myasthenia gravis (MG) is an autoimmune neuromuscular transmission disorder that causes fatigable skeletal muscle weakness. The prevalence ranges from 15 to 230 per million population¹,² and is increasing, in part likely owing to improved diagnosis. MG is commonly divided into clinical subgroups that are determined by for example, age, that is, early onset MG (EOMG; ≤50 years of age) versus late onset MG (LOMG; >50 years of age) or antibody subtype.³,⁴ Furthermore, MG in all age groups (both EOMG and LOMG) can be divided according to clinical manifestations and muscle involved; mainly ocular MG (OMG) versus generalized MG (GMG).⁵ In approximately half of MG patients, the presenting symptoms are purely ocular (ptosis and/or diplopia). Furthermore, involvement of the extraocular muscles occurs in the majority of patients at some point during their disease even when the onset involves other muscle groups.⁶,⁷ The diagnosis of OMG may pose difficulties, as approximately 50% are seronegative for antibodies directed against the acetylcholine receptor (AChR) or muscle specific tyrosine kinase (MuSK) and the clinical signs might initially be mild and difficult to detect.⁸,⁹ Previous retrospective studies reported that up to 80% of patients with purely ocular symptoms at onset develop secondary generalized MG (SGMG),⁵,⁷,⁸ most <2 years from disease onset, and hence those patients with pure ocular symptoms ≥2 years most...
often remain as OMG, in particular older male patients.\textsuperscript{7,8} Previous studies have found subclinical abnormal neuromuscular transmission (increased jitter) also in limb muscles of patients with OMG\textsuperscript{10}; however, predictive factors for the risk of conversion from OMG to SGMG have not been established, in part due to the retrospective nature of previous studies. Nevertheless, patients who are AChR antibody seropositive (AChR+) are likely to be at higher risk for conversion from OMG to SGMG\textsuperscript{11} than AChR antibody seronegative (AChR-) patients.

MicroRNAs (miRNAs) are small noncoding RNAs that have been postulated as potential diagnostic biomarkers of different autoimmune disorders including systemic lupus erythematosus, primary Sjögren’s syndrome, systemic sclerosis, rheumatoid arthritis, and psoriasis.\textsuperscript{12,13} The first reports of miRNAs in MG emerged in 2012.\textsuperscript{14} Subsequent studies have presented a miRNA profiles in serum samples\textsuperscript{15–22} or peripheral blood mononuclear cells (PBMC)\textsuperscript{23–25} from MG patients. Punga et al. described distinct miRNA profiles in the subgroups of AChR+ MG and MuSK+ MG\textsuperscript{17–19} as well as recently also in LOMG.\textsuperscript{20} Furthermore, miR-20b was found decreased in the serum of MG patients in a Chinese cohort and\textsuperscript{15} in another MG patient cohort with various clinical manifestations a set of seven miRNAs (miR-15b, miR-122, miR-140-3p, miR-185, miR-192, miR-20b, and miR-885-5p) were significantly lower in patients compared with healthy controls.\textsuperscript{16} Studies on the prognostic values of miRNAs have been performed predominantly within the oncology field thus far.\textsuperscript{26} In MG, the miRNAs miRNA-150-5p and miRNA-21-5p are dysregulated among GMG patients with EOMG,\textsuperscript{18} although studies in OMG patients are lacking.

Serum antibodies and electrophysiology are important diagnostic biomarkers in MG diagnosis but do not correlate with the disease severity and are impractical in use as outcome measures.\textsuperscript{22,27} Therefore, the aim of the current study was to determine the circulating miRNA profile in serum among patients with OMG in order to identify candidate miRNAs that would serve as potential predictors of disease generalization.

**Methods**

**Subjects**

Between August 2014 and February 2017, 96 consecutive patients with a new diagnosis of OMG were prospectively recruited from UK centers (London, Nottingham, Birmingham and Oxford). For the discovery cohort, five OMG patients were selected and four age- and gender-matched healthy controls (HCs) at Uppsala University Hospital were used as controls in this set (Table 1). All patients and controls were White European. Patient demographic details are shown in Table 2. For the validation cohort, the remaining patients were included.

Ocular myasthenia gravis was diagnosed based on subjective and objective clinical ocular manifestations of ptosis and/or diplopia, antibody detection, pharmacological, and/or electromyography test. The diagnosis of ocular myasthenia was made if the patient had classical ocular symptoms and signs of myasthenia (ptosis and/or diplopia) for at least 3 months, in the absence of an alternative diagnosis. Generalized MG symptoms were excluded at onset by clinical neurological examination. Most patients were AChR antibody positive, either in a radioimmunoprecipitation assay (RIA), or cell-based assay. The minority of patients who were antibody negative had either abnormal Single Fibre EMG studies, indicating disturbed neuromuscular transmission, or in a small number of cases, a positive response to treatment with acetylcholinesterase inhibitors.\textsuperscript{5} Patients with a confirmed diagnosis of MG were eligible if symptoms had been confined to the extraocular muscles for at least 3 months since symptom onset (OMG phenotype). As former studies have indicated, most OMG patients who develop GMG do so during the first 2 years, therefore all the patients were followed up for at least 2 years before classifying them as pure OMG or SGMG patients.

The study was approved by NRES Committee West Midlands – South Birmingham (12/WM/0414) and London (15/LO/0943) and the analysis of serum samples was approved by the Uppsala ethical standards committee on human experimentation (Dnr 2010/446/2). All patients provided signed, informed consent. Serum samples were taken and stored at \(-80^\circ\text{C}\), and myasthenia gravis composite (MGC) scores were recorded at recruitment and at each subsequent 12-month follow-up visit.

**Circulating miRNA isolation**

Blood samples were collected in tubes without any additives, stored at room temperature at least 20 min and centrifuged at room temperature at 1200 g for 5 min. The samples were stored at \(-80^\circ\text{C}\) until further processing. Total RNA was isolated from 200 µL serum. After thawing the samples, they were centrifuged at 150 g for 5 min and RNA isolation was done with miRCURY\textsuperscript{TM}RNA Isolation Kit-Biofluids (Exiqon #300112, Vedbaek, Denmark) according to the manufacturer’s instructions. For serum cDNA synthesis, the Universal cDNA Synthesis Kit II (Exiqon #203301, Vedbaek, Denmark) and 2 µL of isolated RNA was used for cDNA synthesis in 10 µL reaction mix.
miRNA expression analysis

We performed reverse transcription (RT) followed by real-time quantitative PCR using ExiLENT SYBR Green master mix (Exiqon #203421, Vedbaek, Denmark). MicroRNA expression was analyzed using the Serum/Plasma Focus microRNA PCR Panel (V4.M, Exiqon, Vedbaek, Denmark), containing primer sets of 179 human miRNAs, in the discovery cohort. Thirteen selected primers detected from the discovery cohort were added to the PCR plates. The cDNA templates were diluted 50× in nuclease-free water before applying them to the 384-well PCR panel plates. We used control assays that were available in the miRNA qPCR panels: interplate calibration with UniSp3, quality of RNA isolation with UniSp2 and UniSp4, and cDNA synthesis control with UniSp6. Cellular miRNA contamination was controlled in order to exclude hemolysis during the serum sample preparation. ΔCq (miR-23a–miR-451a) <7 represented non-hemolyzed samples. The reference candidates in the study were miR-103a-3p, miR-191-3p, miR-93-3p, and miR-423-4p. Comparative CT method was used to quantify miRNA using the formula 2−ΔΔCT where ΔΔCT = (CT gene of interest–CT reference gene). Normalization was performed to miR-191-5p as other normalizing genes were not abundantly detected in all samples and since it was recommended as normalizing gene by GenEx. Initial miRNA detection experiments that were performed on the Serum/Plasma Focus microRNA PCR Panel profiled the genes of interest from 179 different miRNAs. From these 30 genes that were significantly different among OMG patients compared to the HCs (Fig. 1), 12 were selected for further analysis based on earlier research in connection with miRNAs and autoimmunity. Specifically referring to previous data obtained with miR150-5p and miR-30e-5p in AChR+ EOMG and LOMG that also included OMG patients, these two miRNAs were added to the list of the genes of interest in the validation cohort.

Statistical analysis

Log conversion of the data in the discovery set was done in order to obtain data more similar to a normal distribution for the statistical tests. Unpaired two-tailed T-test of independent samples was performed, comparing OMG and control groups with the null hypothesis that the mean values of the different miRNAs were the same across OMG and control categories. Mann–Whitney U test was performed in case of nonparametric data. In the discovery set, candidate miRNAs were selected if they were found to be significantly different expressed in the OMG versus control group. In addition to those differentially expressed, only miRNAs that were found to be up- or downregulated in each individual patient were selected for the validation set analysis. The null hypothesis for the predictive sensitivity of the dysregulated miRNAs, using ROC curve, indicates a true area of 0.5. Spearman Rank correlation was performed to analyze correlation between continuous factors (age, disease duration, disease severity) and the miRNAs tested. Statistical significance was defined as P < 0.05.

Results

Specific circulating miRNA profile in the OMG discovery cohort

In the discovery cohort of five OMG patients and four sex- and age-matched healthy controls (Table 1), no hemolysis was detected. All the discovery cohort patients remained ocular for more than 2 years after diagnosis (from 2.5 to 4.8 years) and median followed-up time was median 52.5 months (IQR 30.2–59.0 months). Thirty miRNAs were strongly elevated in the OMG cohort (Table S1) and of these, 19 miRNAs, in addition to miR-150-5p and miR-30e-5p, were further analyzed by qRT-PCR in sera from a larger UK validation cohort of OMG patients.
miR-30e-5p Predicts Generalization in OMG

L. Sabre et al.

Table 2. Demographic data of myasthenia gravis (MG) patients in the final validation cohort (including only samples that did not have hemolysis).

| Characteristic                              | N = 83 |
|--------------------------------------------|--------|
| Age at MG onset (years; mean ± SD)         | 54.5 ± 15.2 |
| Duration of MG symptoms (months; median; IQR) | 42.6 (32.1–52.8) |
| Gender N (%)                               |        |
| Male                                       | 49 (59%) |
| Female                                     | 34 (41%) |
| Antibody subgroup N (%)                    |        |
| AChR+                                      | 57 (68.7%) |
| RIA                                        | 52 (91.2%) |
| CBA                                        | 5 (8.8%) |
| MuSK+                                      | 8 (9.6%) |
| RiA                                        | 0 (0%) |
| CBA                                        | 8 (100%) |
| LRP4+                                      | 2 (2.4%) |
| CBA                                        | 2 (100%) |
| Seronegative                                | 16 (19.3%) |
| Initial MGC score (mean ± SD)              | 3.7 ± 2.7 |
| Prednisone treatment N (%)                 | 1 (1.2%) |

IQR, interquartile range; EOMG, early onset MG; LOMG, late onset MG; OMG, ocular MG; SGMG, secondary generalized MG, AChR+, acetylcholine receptor antibody positive; RIA, radioimmunoassay; CBA, cell-based assay; MuSK, muscle specific tyrosine kinase; LRP4, lipoprotein receptor-related protein 4; seronegative, no detectable serum antibodies against AChR, MuSK or LRP4; MGC, MG Composite score. Duration of MG symptoms, time from first symptom to most recent follow-up.

Characteristics of the prospective validation cohort of OMG

In the validation cohort, the hemolysis quote was >7 in 12 samples and these were thus excluded from further analysis. The final validation cohort therefore consisted of 83 OMG patients (49 men and 34 women; Table 2). All patients had purely ocular symptoms within 3 months from the diagnosis. Thirteen patients generalized 14.8 ± 12.0 months (range 3–38.3) after the diagnosis and the majority (85%) belonged to the LOMG group. Initially, 68.7% of OMG patients were AChR+; 9.6% were MuSK+ and the remaining 19.3% were AChR-/MuSK-. Almost all (92%) patients whose disease generalized during the follow-up were AChR+ and one patient was MuSK+. Ninety-nine percent of patients were treated-naive at the time of sampling; one patient was given prednisolone before the blood sample was drawn, however it was stopped 1 week before blood sampling. None of the patients that generalized had taken prednisone before the disease generalized. Five patients had thymectomy during follow-up (thymic hyperplasia in two, thymoma in two, and atrophic thymus in one). The mean MGC score at recruitment was 3.7 ± 2.7, being significantly higher among patients whose disease generalized (5.5 ± 3.4 vs. 3.3 ± 2.5, P = 0.009). Median duration of follow-up from first symptoms was 47.4 months with interquartile range (IQR) 34.0–62.4.

Median duration of symptoms had been shorter in SGMG patients before they were recruited (5.3 (IQR 4.2; 8.6) vs. 12.0 (5.5; 24) months, P = 0.02). Still, all the SGMG patients had only ocular symptoms at the recruitment.

Elevated circulating miRNA miR-30e-5p identifies OMG patients at risk for generalization

In comparing circulating miRNA levels among the entire patient cohort with OMG and SGMG, miR-30e-5p levels were significantly higher among SGMG patients (9.0 ± 0.5) than among OMG patients (6.5 ± 1.4; P < 0.0001; Fig. 2A). None of the remaining miRNAs showed significant difference between OMG and SGMG patients. Subgroup analysis in LOMG patients (N = 50) revealed that two miRNAs significantly differed between OMG and SGMG patients (Table 3), miR-30e-5p (6.3 ± 0.9 vs. 9.1 ± 0.5; P < 0.0001; Fig. 2B) and miR-150-5p (6.4 ± 1.1 vs. 7.4 ± 1.1; P = 0.01; Fig. 2C). The area under the ROC curve for miR-30e-5p was 0.96 (95% CI: 0.92–1.0; P < 0.0001; Fig. 2D) for all OMG patients and 1.0 for the LOMG cohort (95% CI: 1.0–1.0; P < 0.0001; Fig. 2E). Therefore, based on the different IQR values and the ROC curve, the predictive value for all OMG patients to generalize was 96% and for LOMG patients 100% for a cutoff >8 for miR-30e-5p, whereas no particular cut-off was identified for miR-150-5p due to overlap between the groups. For patients who had positive AChR ab on RIA, there was no difference in AChR ab titers between OMG (N = 23) and SGMG (N = 10) patients (124.6 ± 18.1 vs. 62.6 ± 27.2; P = 0.07); thus, we found no predictive value for generalization regarding ab titer (Figure S1).

We did not find any correlation between miRNAs and any other clinical features, such as age, MGC score or disease duration (P > 0.05 for all).

Discussion

Depending on the distribution of fatigable skeletal muscle weakness in relation to extraocular muscles, MG can be
classified into the subgroups OMG or GMG. The number of patients converting from OMG to GMG varies widely, between 30% and 80%, in retrospective studies.\textsuperscript{6,29} This large range likely reflects the heterogeneity of patient groups and the retrospective nature of the studies. The patients in this cohort were recruited prospectively at around the time of diagnosis, and followed up for 2 years or more. Many OMG patients in this cohort were identified early due to the clinical set up in London, where patients with ocular symptoms self-present to the Eye Emergency Department and are then referred onwards to the Neuro-Ophthalmology department.

To the best of our knowledge, this is the first study that has identified a potential predictive biomarker that can predict which OMG patients will generalize. Prognostic markers to stratify patients into high- or low-risk of conversion from OMG to GMG are important and may even guide future therapeutic decisions.\textsuperscript{30} This is particularly relevant clinically as some retrospective studies have raised the possibility that starting treatment with immunosuppression early may alter the risk of conversion from OMG to GMG.\textsuperscript{9,30} None of the patients who generalized were on prednisone treatment. Our study provides evidence that miR-30e-5p could serve as a potential predictive biomarker for the future conversion from OMG to GMG, at least in LOMG. The risk of generalization was 100% in OMG cases with levels of miR-30e-5p >8 shortly after disease onset. This is in line with a very
**Figure 2.** Relative mRNA expression of differently altered miRNAs miR-30e-5p in all OMG patients (A). Levels of miR-30e-5p (B) and miR-150-5p (C) in late-onset OMG patients were analyzed with unpaired T test between the OMG and SGMG groups. ROC curves of miR-30e-5p, indicating sensitivity for OMG versus SGMG in the entire cohort (D) and in the late onset MG (LOMG) cohort (E). OMG, ocular myasthenia gravis; SGMG, secondary generalized myasthenia gravis. *P < 0.05; ***P < 0.001.
Although the exact role of miR-30e-5p in humans needs further elaboration, elevated levels of miR-30e-5p could hypothetically reduce the expression of important proteins involved in maintaining skeletal muscle homeostasis and metabolism.

In general, at least 3 months duration of isolated ocular symptoms is considered a reasonable time period to diagnose OMG.7,9 Nevertheless, the question to be asked is whether there is a window of inhibiting generalization. Considering that there is the potential to modify the progression to GMG with corticosteroids34 and SGMG develops in up to 50% of OMG patients within 1 year,35 how would one know the best intervention strategy? The suggestion for a minimum of 3 months to define patients as OMG was proposed in 1989 by Oosterhuis.36 Therefore, we included patients whose ocular symptoms had extended at least 3 months or who did not generalize earlier than 3 months. Most of the patients who generalized (~90%) during the follow-up period were AChR+, and thus our study supported previous findings of older age at onset as well as AChR antibody seropositivity as factors associated with a greater likelihood of generalization.9,37 Nevertheless, we did not find any cutoff regarding AChR antibody titer in the SGMG group compared to the OMG group. In addition, we also found 10% MuSK+ OMG patients, although in contrast to Evoli et al.38 only one patient progressed to secondary GMG during the follow-up. We did not find a difference in sex regarding generalization frequency in our study.

In conclusion, this is the first study that found a potential predictor of which patients who develop GMG from OMG. We propose miR-30e-5p as this predictor, with 96% sensitivity in all OMG patients and 100% sensitivity in late onset OMG patients.

Table 3. Mean circulating longitudinal miRNAs levels among ocular and secondary generalized LOMG patients.

|          | OMG (N = 40) | SGMG (11) | P value |
|----------|--------------|-----------|---------|
| hsa-miR-15b-5p | 5.9 ± 1.9 | 5.8 ± 1.4 | 0.93    |
| hsa-miR-21-5p | 11.3 ± 1.3 | 11.6 ± 0.9 | 0.40    |
| hsa-miR-424-5p | 8.2 ± 1.8 | 7.3 ± 1.0 | 0.11    |
| hsa-miR-532-3p | 4.0 ± 1.6 | 3.8 ± 0.9 | 0.75    |
| hsa-miR-148a-3p | 7.6 ± 1.4 | 7.8 ± 1.1 | 0.71    |
| hsa-miR-34a-5p | 3.2 ± 1.9 | 3.5 ± 3.1 | 0.83    |
| hsa-miR-19a-3p | 8.7 ± 1.7 | 8.6 ± 1.0 | 0.86    |
| hsa-miR-19b-3p | 10.7 ± 1.7 | 11.3 ± 1.3 | 0.30    |
| hsa-miR-140-5p | 5.6 ± 1.9 | 5.2 ± 1.5 | 0.64    |
| hsa-miR-30e-5p | 6.3 ± 0.9 | 9.1 ± 0.5 | <0.0001 |
| hsa-miR-223-3p | 13.0 ± 1.5 | 12.6 ± 2.3 | 0.58    |
| hsa-miR-150-5p | 6.4 ± 1.1 | 7.4 ± 1.1 | 0.01    |
| hsa-miR-223-5p | 3.6 ± 1.8 | 3.1 ± 0.7 | 0.47    |

OMG, ocular myasthenia gravis; SGMG, secondary generalized myasthenia gravis; LOMG, late-onset myasthenia gravis. *P*-values in bold indicate significantly different miRNAs between the groups.

recent study that indicated miR-30e-5p as a potential biomarker in LOMG.20 This particular miRNA has previously been found downregulated in patients with AChR+ EOMG patients compared to healthy controls.17 Consequently, one reason as to why miR-30e-5p was not significantly elevated in the OMG discovery cohort compared to the healthy controls could be that two of these OMG patients had EOMG and not LOMG, as was the case for the majority of the validation cohort.

In the previously analyzed cohort of LOMG patients, miR-30e-5p levels were not significantly different between SGMG and OMG patients. Here, we found that miR-30e-5p levels significantly differed between OMG and SGMG patients in the LOMG cohort. One reason for this could be that patients who rapidly develop GMG have a different pathogenesis of MG from those that remain with OMG.9 Furthermore, the SGMG patients in our previous study were generalized already at recruitment and were longitudinally compared to OMG patients.20

Intriguingly, the low-density lipoprotein receptor-related protein 6 (LRP6), one of the critical co-receptors for Wnts (a family of genes that encode secretory glycoproteins), is a direct target of miR-30e.31 The Wnt signaling pathway is involved in development, proliferation, differentiation, adhesion and cellular polarity. Importantly, the canonical Wnt/β-catenin signaling can regulate multiple steps of myogenesis, including cell proliferation as well as myoblast fusion and homeostasis.32 In a transcriptome analysis of pig skeletal muscles, miR-30e-5p was associated with the muscle protein PPARGC1A that plays an important role in mitochondrial biogenesis.33

© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
miR-30e-5p Predicts Generalization in OMG

L. Sabre et al.

Acknowledgments

The study was funded by the Swedish Research Council (VR-523-2014-2048 to ARP).

Conflict of Interest

None declared.

References

1. Carr AS, Cardwell CR, McCarroll PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46.
2. Sabre L, Westerberg E, Liik M, et al. Diversity in mental fatigue and social profile of patients with myasthenia gravis in two different Northern European countries. Brain Behav 2017;4:e00653.
3. Evoli A, Batocchi AP, Minisci C, et al. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 2000;48:1442–1448.
4. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Neurology 2015;10:1023–1036.
5. Kerty E, Elsais A, Argov Z, et al. EFNS/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol 2014;5:687–693.
6. Bever CT Jr, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983;5:516–519.
7. Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008;2:141–149.
8. Kusner LL, Puwanant A, Kaminski HJ. Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist 2006;5:231–239.
9. Wong SH, Huda S, Vincent A, et al. Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep 2014;1:421.
10. Rostedt A, Saders LL, Edards LJ, et al. Predictive value of single-fiber electromyography in the extensor digitorum communis muscle of patients with ocular myasthenia gravis: a retrospective study. J Clin Neuromuscul Dis 2000;1:6–9.
11. Wong SH, Petrie A, Plant GT. Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification. J Neuroophthalmol 2016;3:252–258.
12. Chen JQ, Papp G, Szodoray P, et al. The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev 2016;12:1171–1180.
13. Garo LP, Murugaiyan G. Contribution of MicroRNAs to autoimmune diseases. Cell Mol Life Sci 2016;10:2041–2051.
14. Jiang L, Cheng Z, Qiu S, et al. Altered let-7 expression in myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. Int Immunopharmacol 2012;2:217–223.
15. Chunjie N, Huijuan N, Zhao Y, et al. Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients. Eur Cytokine Netw 2015;3:61–66.
16. Nogales-Gadea G, Ramos-Fransi A, Suarez-Calvet X, et al. Analysis of serum miRNA profiles of myasthenia gravis patients. PLoS ONE 2014;3:e91927.
17. Punga T, Le Panse R, Andersson M, et al. Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann Clin Transl Neurol 2014;1:49–58.
18. Punga AR, Andersson M, Alimohammadi M, et al. Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. J Neurol Sci 2015;1:290–96.
19. Punga T, Bartoccioni E, Lewandowska M, et al. Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. J Neuroimmunol 2016;292:21–26.
20. Sabre L, Maddison P, Sadalage G, et al. Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis. J Neuroimmunol 2018;321:164–170.
21. Molin CJ, Sabre L, Weis CA, et al. Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Neuroimmunol Neuroinflamm 2018;3:e450.
22. Punga AR, Punga T. Circulating microRNAs as potential biomarkers in myasthenia gravis patients. Ann NY Acad Sci 2018;1:33–40.
23. Cheng Z, Qiu S, Jiang L, et al. MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1. J Clin Immunol 2013;3:567–576.
24. Liu XF, Wang RQ, Hu B, et al. MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10. Clin Immunol 2016;164:106–113.
25. Lu J, Yan M, Wang Y, et al. Altered expression of miR-146a in myasthenia gravis. Neurosci Lett 2013;555:85–90.
26. Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014;3:145–156.
27. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;5:475–490.
28. Marabita F, de Candia P, Torri A, et al. Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform 2016;2:204–212.
29. Weizer JS, Lee AG, Coats DK. Myasthenia gravis with ocular involvement in older patients. Can J Ophthalmol 2001;1:26–33.
30. Wong SH, Plant GT, Cornblath W. Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients? J Neuroophthalmol 2016;1:98–102.

31. Wang J, Guan X, Guo F, et al. miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6. Cell Death Dis 2013;4:e845.

32. Suzuki A, Pelikan RC, Iwata J. WNT/beta-catenin signaling regulates multiple steps of myogenesis by regulating step-specific targets. Mol Cell Biol 2015;10:1763–1776.

33. Jing L, Hou Y, Wu H, et al. Transcriptome analysis of mRNA and miRNA in skeletal muscle indicates an important network for differential Residual Feed Intake in pigs. Sci Rep 2015;5:11953.

34. Kupersmith MJ. Does early immunotherapy reduce the conversion of ocular myasthenia gravis to generalized myasthenia gravis? J Neuroophthalmol 2003;4:249–250.

35. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 2009;8:1314–1320.

36. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989;10:1121–1127.

37. Mazzoli M, Ariatti A, Valzania F, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 2018;1:15–24.

38. Evoli A, Alboini PE, Iorio R, et al. Pattern of ocular involvement in myasthenia gravis with MuSK antibodies. J Neurol Neurosurg Psychiatry 2017;9:761–763.

39. Kroesen BJ, Teteloshvili N, Smigielska-Czepiel K, et al. Immuno-miRs: critical regulators of T-cell development, function and ageing. Immunology 2015;1:1–10.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Acetylcholine receptor antibody (AChR ab) titer as measured by radioimmunoprecipitation assay in nM. OMG, ocular myasthenia gravis; SGMG, secondary generalized myasthenia gravis.

Table S1. Differentially expressed miRNAs in ocular MG discovery set. Significantly different microRNAs (in bold) were selected for further analysis in validation set (P < 0.05).